Search Results - "Fishman, Marc"

Patient Characteristics Associated with Successful Initiation of Extended-Release Naltrexone in the X:BOT Trial.

Authors: Potter, Kenzie Greiner, Miranda Shulman, Matisyahu et al.

Source: Substance Use & Misuse. 2026, Vol. 61 Issue 10, p1662-1671.

A comparative study of treatment retention in opioid use disorder: Subcutaneous injectable versus sublingual buprenorphine.

Authors: Deng, Charles Oviedo, Enrique Fishman, Marc et al.

Source: Addiction. Oct2025, Vol. 120 Issue 10, p2127-2133.

Evidence Base on Outpatient Behavioral Treatments for Adolescent Substance Use, Update 2018–2023: Current Status, Best Practices, and Opportunities for Advancing the Science.

Authors: Hogue, Aaron Porter, Nicole P. Henderson, Craig E. et al.

Source: Journal of Clinical Child & Adolescent Psychology. May/Jun2026, Vol. 55 Issue 3, p391-415. 25p.

Subjects: Motivational interviewing, Opioid abuse, Cognitive therapy, Family psychotherapy, Outpatient medical care, Marijuana abuse, Underage drinking, Behavior therapy

A pilot test of Written Exposure Therapy for PTSD in residential substance use treatment.

Authors: Schacht, Rebecca L. Wenzel, Kevin R. Meyer, Laurel E. et al.

Source: American Journal on Addictions. Sep2023, Vol. 32 Issue 5, p488-496.

Trajectories of depression among patients in treatment for opioid use disorder: A growth mixture model secondary analysis of the XBOT trial.

Authors: Vest, Noel Wenzel, Kevin Choo, Tse‐Hwei et al.

Source: American Journal on Addictions. May2023, Vol. 32 Issue 3, p291-300.

Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone.

Authors: Greiner, Miranda G. Shulman, Matisyahu Scodes, Jennifer et al.

Source: Substance Use & Misuse. 2022, Vol. 57 Issue 11, p1732-1742.

Opioid overdose experiences in a sample of US adolescents and young adults: a thematic analysis.

Authors: Monico, Laura B. Ludwig, Ariel Lertch, Elizabeth et al.

Source: Addiction. Apr2021, Vol. 116 Issue 4, p865-873.

A pilot randomized controlled trial of assertive treatment including family involvement and home delivery of medication for young adults with opioid use disorder.

Authors: Fishman, Marc Wenzel, Kevin Vo, Hoa et al.

Source: Addiction. Mar2021, Vol. 116 Issue 3, p548-557.

Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse.

Authors: Rudolph, Kara E. Shulman, Matisyahu Fishman, Marc et al.

Source: Addiction. Mar2022, Vol. 117 Issue 3, p637-645.

Examination of Correlates of OUD Outcomes in Young Adults: Secondary Analysis From the XBOT Trial.

Authors: Fishman, Marc Wenzel, Kevin Scodes, Jennifer et al.

Source: American Journal on Addictions. Sep2021, Vol. 30 Issue 5, p433-444.

Trait Mindfulness and Progression to Injection Use in Youth With Opioid Addiction.

Authors: Wilson, J. Deanna Vo, Hoa Matson, Pamela et al.

Source: Substance Use & Misuse. 2017, Vol. 52 Issue 11, p1486-1493. 8p. 2 Charts.

Subjects: Intravenous drug abuse, Affective disorders, Narcotics, Regression analysis, Cross-sectional method, Mindfulness

Lack of Premeditation Mediates the Relationship Between Adverse Childhood Experiences and Posttraumatic Stress Disorder in Individuals in Residential Treatment for Substance Use Disorder.

Authors: Thomas, Julia Carrano, Jennifer Schacht, Rebecca L. et al.

Source: Journal of Dual Diagnosis. Jan-Mar2025, Vol. 21 Issue 1, p3-12. 10p.

Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility.

Authors: Fishman, Marc J. Winstanley, Erin L. Curran, Erin et al.

Source: Addiction. Sep2010, Vol. 105 Issue 9, p1669-1676.

Depressive symptoms in adolescents during residential treatment for substance use disorders.

Authors: Subramaniam, Geetha A. Lewis, Lindy L. Stitzer, Maxine L. et al.

Source: American Journal on Addictions. May/Jun2004, Vol. 13 Issue 3, p256-267.

Fentanyl‐induced respiratory depression in rodents is inhibited by bioabsorbable, subcutaneous naltrexone implants at 3.5 months.

Authors: Benner, Jeffrey D. Cohen, Steven M. Hollenbaugh, Joseph A. et al.

Source: Addiction Biology. Dec2023, Vol. 28 Issue 12, p1-9. 9p.

Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone.

Authors: Fishman, Marc¹ (AUTHOR)

Source: Addiction. Aug2008, Vol. 103 Issue 8, p1399-1401.

Author Index.

Source: Academic emergency medicine: official journal of the Society for Academic Emergency Medicine May2025 Supplement 1; Vol. 32.

Journal Info: Publisher: Wiley-Blackwell ISSN: 1069-6563

Bioabsorbable, subcutaneous naltrexone implants mitigate fentanyl‐induced respiratory depression at 3 months—A pilot study in male canines.

Authors: Joyner, Robert L. Hollenbaugh, Joseph A. D'Aquila, Donald et al.

Source: Physiological Reports. Aug2024, Vol. 12 Issue 15, p1-13. 13p.

Mood disorders in HIV infection.

Authors: Treisman, Glenn Fishman, Marc Schwartz, Joseph et al.

Source: Depression & Anxiety (1091-4269). 1998, Vol. 7 Issue 4, p178-187. 10p.

Subjects: HIV-positive persons, HIV infections, Affective disorders, Mental depression, Pathological psychology

Mood disorders in HIV infection.

Authors: Fishman, Marc Lyketsos, Constantine G.

Source: International Review of Psychiatry. Sep96, Vol. 8 Issue 2/3, p267. 10p. 1 Diagram.

Subjects: Affective disorders, Mental health services, HIV infections & psychology